Sylvain Roy

Sylvain Roy possesses extensive experience in the biotechnology and pharmaceutical industries, with a focus on manufacturing operations and technical services. Currently serving as Executive Director of CMC Portfolio & Strategy for Cell Therapy at AstraZeneca since May 2025, previous roles include Chief Technology Officer at ImmPACT Bio and Vice President of Manufacturing Operations at ImmunityBio. Sylvain has a robust background in managing complex manufacturing operations and strategic partnerships, demonstrated through successful oversight of N-803 project execution and significant contributions to product lifecycle management at Shire and Baxalta. With a master's degree in Biotechnology and Biochemistry Engineering from INSA Lyon and a bachelor's degree in Biology & Biochemistry from Université Claude Bernard Lyon 1, Sylvain has consistently driven innovation and operational excellence across various organizations, including NantKwest, Baxter Healthcare, and Merial.